Urology research grant focused on improving patient care

CUA Astellas Research Grant Program now accepting proposals for 2013 
competition 
MARKHAM, ON, Dec. 12, 2012 /CNW/ - Improving patient care is the ultimate goal 
of a research grant program, designed to support Canadian scientific discovery 
and innovation in urology. 
Researchers are invited to submit a proposal to the CUA Astellas Research 
Grant Program, a joint initiative of the Canadian Urological Association (CUA) 
and Astellas Pharma Canada, Inc. (Astellas). 
This is the second year of the grant program, which supports peer-reviewed 
research and promotes excellence in urological research. Astellas has pledged 
$750,000 CND over a period of five years to support Canadian investigators in 
urology. 
For the 2013 competition, the primary focus is to support research in 
functional urology, including overactive bladder (OAB), lower urinary tract 
symptoms (LUTS), pelvic floor disorders, voiding dysfunctions, and neurogenic 
bladder. The secondary focus is to support other urology research areas such 
as urologic cancer and other community-based research. 
Three research grants will be awarded (each with a maximum value of $50,000 
CDN) based on scientific validity, integrity, clinical relevance, and 
feasibility. Grant recipients are expected to demonstrate improved 
understanding of the specific research area and/or directly contribute to 
improving patient care. 
Dr. Blayne Welk, a 2012 grant recipient based at University of Western 
Ontario, says the funding has provided him with an exciting opportunity to 
pursue his research interests among patients with neurogenic bladder 
dysfunction. 
"I am sure the CUA Astellas grant's commitment to support voiding dysfunction 
research will inspire new researchers with an interest in this area and build 
on existing high-quality Canadian research," Welk says. 
Dr. Ben Chew, also a 2012 grant recipient, strongly encourages other Canadian 
urology researchers to apply to the grant program. He says his laboratory at 
the University of British Columbia is most appreciative of this funding, 
adding that it "really relays the commitment that Astellas has to supporting 
urologists, research, and ultimately patients and their health." 
"With these funds, it will allow us to fund enough experiments to obtain 
important preliminary data and then apply for national funding agencies such 
as CIHR or NSERC for further funding," says Chew, whose research is on the 
physiology of ureteral peristalsis and the effects of stone passage and 
ureteral stent insertion. "Without money from the CUA Astellas Research Grant, 
our research would not be able to expand." 
Michael Tremblay, President of Astellas Pharma Canada, Inc., says Astellas is 
proud to support the efforts of researchers in the Canadian urology community 
because of the direct impact their work will have on patient care and health. 
"Quality of life is a huge issue for patients with urologic conditions," says 
Tremblay. "Through Astellas' grant partnership with the CUA, it is our hope 
that the resulting research will ultimately lead to ground-breaking new 
therapies that will transform patient lives - that is what it is all about." 
For more information about the CUA Astellas Research Grant, including 
eligibility criteria and the application process, please visit www.cua.org or 
www.astellas.ca. The deadline to submit a research proposal is January 13, 
2013, at 5 p.m. EST. 
About the Canadian Urological Association (CUA)
The CUA Mission is to represent and provide a voice for all Canadian 
urologists and to foster dedication of all members of the profession toward 
ensuring the highest possible standard of urologic care for Canadians. 
The goals of the CUA are:  


    --  To foster and promote excellence in urologic practice through
        education and research.
    --  To provide leadership in promoting evidence based clinical
        practice through the development of practice guidelines.
    --  To foster and promote life-long learning by Canadian urologists
        through continuous professional development.
    --  To provide leadership in public education for urologic
        diseases.
    --  To represent Canadian urology in developing and fostering
        partnerships while maintaining the highest educational and
        ethical standards.
    --  To represent the Canadian urologic community in relationships
        with national and international medical societies.

More information about CUA can be found at www.cua.org

About Astellas Pharma Canada, Inc.
Astellas Pharma Canada, Inc., headquartered in Markham, ON, is a Canadian 
affiliate of Tokyo-based Astellas Pharma Inc. Astellas is a pharmaceutical 
company dedicated to improving the health of people around the world through 
the provision of innovative and reliable pharmaceutical products.

The organization is committed to becoming a global category leader in focused 
areas by combining outstanding R&D and marketing capabilities. In Canada, 
Astellas has an intense commercial focus on five therapeutic areas - Urology, 
Immunology, Infectious Disease, Dermatology and Oncology.

For more information about Astellas Pharma Canada, Inc., please visit the 
corporate website: www.astellas.ca

Naomi Côté Corporate Communications Astellas Pharma Canada, Inc. (905) 
946-5621 naomi.cote@astellas.com

Tiffany Pizioli Executive Director, CUA Office of Education Canadian 
Urological Association (514) 395-0376 ext. 44 tiffany.pizioli@cua.org

SOURCE: Astellas Pharma Canada, Inc.

To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/December2012/12/c7804.html

CO: Astellas Pharma Canada, Inc.
ST: Quebec
NI: MTC HEA 

-0- Dec/12/2012 13:30 GMT


 
Press spacebar to pause and continue. Press esc to stop.